OpenScience.ink

1 week ago • Clinics in dermatology

Ethical Issues of Using GLP-1 Receptor Drugs in Skin TreatmentsGLP-1 Receptor Agonists in Dermatology: Ethical Considerations.

📖 Top 50% JournalArticle

1 week ago • Pharmaceutical development and technology

Creating Stable Microspheres to Deliver Exenatide Using Polarity Gradient ExtractionDevelopment of Chondroitin Sulfate ‑ Stabilized PLGA Microspheres of Exenatide via Polarity Gradient Extraction.

📖 Top 50% JournalArticle

1 week ago • Immunopharmacology and immunotoxicology

Improvement of post-COVID-19 vaccination nerve system imbalance with GLP-1 receptor activatorImprovement of post-COVID-19 vaccination dysautonomia with GLP-1 receptor agonist.

📖 Top 30% JournalArticle

1 week ago • High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension

Loss of Muscle During Weight Loss with Glucagon-like Peptide-1 Treatments: Rethinking Its ImportanceLean Mass Reduction During Glucagon-like Peptide-1 Receptor Agonists-Induced Weight Loss: Rethinking Its Clinical Significance.

📖 Top 20% JournalArticle

2 weeks ago • Pulmonary therapy

How Diabetes Drugs May Affect Immune and Metabolic Responses in Obese AsthmaImmunometabolic Modulation in Obese Asthma: How GLP-1 Receptor Agonists Could Influence Systemic and Pulmonary Immune Phenotypes.

📖 Top 20% JournalArticle

2 weeks ago • Clinics in dermatology

Skin Reactions and Injection Site Problems Linked to Glucagon-like Peptide-1 Receptor Agonist UseGlucagon-like Peptide-1 Receptor Agonist-Associated Injection Site and Dermatologic Reactions.

📖 Top 50% JournalArticle

2 weeks ago • The Orthopedic clinics of North America

Use of Glucagon-like Peptide-1 Receptor Agonists May Lower Disease Activity and Slow Progression in Osteoarthritis and Inflammatory ArthritisGlucagon-like Peptide-1 Receptor Agonist Use May Reduce Disease Activity and Progression in Osteoarthritis and Inflammatory Arthritis.

📖 Top 30% JournalArticle

2 weeks ago • JMIR diabetes

Social Media Talk about Diabetes Medicines and the Popularity of GLP-1 TreatmentsSocial Media Discussions of Anti-Diabetic Drugs and the Popularity of GLP-1 Therapies: Content Analysis.

📖 Top 20% JournalArticle

2 weeks ago • Journal of clinical neurology (Seoul, Korea)

Use of Glucagon-Like Peptide-1 Receptor Agonists After Mini-Stroke and Its Link to Risk of Later Stroke and DeathEffects of Glucagon-Like Peptide-1 Receptor Agonist Use After Transient Ischemic Attack on Risks of Subsequent Ischemic Stroke and Mortality.

📖 Top 20% JournalArticle

2 weeks ago • Obesity science & practice

Patients' experiences of continuing GLP-1 receptor agonist treatmentPatient-Reported Continuity of GLP-1 Receptor Agonist Therapy.

📖 Top 30% JournalArticle

2 weeks ago • Clinics in dermatology

GLP-1 Receptor Agonists as Treatments for Skin Conditions Linked to Other DiseasesWhere the Future Lies: GLP-1 Receptor Agonists as Therapeutics for Dermatologic Comorbidities.

📖 Top 50% JournalArticle

2 weeks ago • Journal of Yeungnam medical science

Muscle loss linked to metabolism and mitochondria during incretin-based treatment: causes and new therapy ideasMetabolic sarcopenia in the era of incretin-based therapy: a narrative review of mitochondrial determinants of muscle quality and emerging therapeutic strategies.

📖 Top 50% JournalArticle

2 weeks ago • Journal of diabetes and its complications

Semaglutide and empagliflozin effects on blood vessel health markers in people with type 2 diabetesEffects of semaglutide and empagliflozin on markers of endothelial function in persons with type 2 diabetes: A post hoc analysis of a randomized clinical trial.

📖 Top 20% JournalArticle

3 weeks ago • Diabetes therapy : research, treatment and education of diabetes and related disorders

How SGLT2 Inhibitors May Help Prevent Type 2 Diabetes: A Review of Current EvidenceThe Role of SGLT2 Inhibitors in the Prevention of Type 2 Diabetes: A Narrative Review of Current Evidence.

📖 Top 20% JournalArticle

3 weeks ago • The American journal of managed care

Predicting When People Stop Using GLP-1 Medications Based on Pharmacy RecordsPredicting GLP-1 Discontinuation From Pharmacy Claims.

📖 Top 30% JournalArticle

3 weeks ago • Pediatric dermatology

Skin Side Effects of GLP-1 Medicines in Children: New Age-Related Patterns and What Dermatologists Should KnowAre Pediatric GLP-1 Receptor Agonist Cutaneous Adverse Events Being Overlooked? Emerging Age-Specific Patterns and Their Implications for Dermatologists.

📖 Top 50% JournalArticle

3 weeks ago • Clinical medicine insights. Endocrinology and diabetes

Real-World Comparison of GLP-1RA and SGLT2-Inhibitor Treatment Versus Standard CareReal-World Evidence of the GLP-1RA/SGLT2-i Therapy versus Standard Care: A Retrospective Cohort Study.

📖 Top 30% JournalArticle

3 weeks ago • The American journal of managed care

Changes in Semaglutide Prescriptions After New FDA and Medicare RulesChanges in Semaglutide Fills Following Expanded FDA and Medicare Policies.

📖 Top 30% JournalArticle

3 weeks ago • Physiological genomics

How sex and endurance exercise affect hormone signaling that controls insulin in 17 rat tissuesThe effect of sex and endurance exercise training on the incretin signaling pathway in 17 rat tissues.

📖 Top 20% JournalArticle

3 weeks ago • European journal of hospital pharmacy : science and practice

Severe drop in white blood cells linked to Semaglutide needing hospital treatment and growth factor support: a case reportSemaglutide-associated agranulocytosis requiring hospitalisation and granulocyte colony-stimulating factor: a case report.

📖 Top 50% JournalArticle

4 weeks ago • Naunyn-Schmiedeberg's archives of pharmacology

Mental health and eye problems linked to use of GLP-1 receptor drugsPsychiatric and eye disorders associated with use of glucagon-like peptide 1 receptor agonists (GLP-1 RAs).

📖 Top 30% JournalArticle

1 month ago • Neuromolecular medicine

Semaglutide may reduce inflammation-related memory problems by modifying key cell signaling proteinsSemaglutide Alleviates LPS-Induced Cognitive Disorder via O-GlcNAcylation of AKT-mTOR Signaling Pathway Components.

📖 Top 20% JournalArticle

1 month ago • Skin appendage disorders

Hair Loss Linked to GLP-1 Receptor Agonists: Review of How Often It Happens, Types, Risks, and Possible CausesGLP-1 Receptor Agonists and Alopecia: A Systematic Review and Meta-Analysis of Incidence, Risk, Subtypes, and Mechanisms.

📖 Top 50% JournalArticle

2 weeks ago • Clinical medicine insights. Case reports

Liraglutide may reverse tamoxifen-related weight gain and metabolism problems in a breast cancer survivorSuccessful Reversal of Tamoxifen-Associated Weight Gain and Metabolic Dysfunction with Liraglutide in a Breast Cancer Survivor: A Case Report.

Case Reports

2 weeks ago • Nature

Semaglutide treatment later in life slows aging and extends lifespan in female miceLate-life semaglutide treatment slows ageing and extends lifespan in female mice.

Article

2 weeks ago • Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine

Tirzepatide’s links to changes in sleep apnea measures based on starting patient traitsAssociation of tirzepatide with changes in OSA-related measures based on baseline characteristics - post hoc analyses of SURMOUNT-OSA.

Randomized Controlled Trial

3 days ago • Journal of gastrointestinal cancer

Long-Term Use of GLP-1 Receptor Agonists and Risk of Developing Pancreatic CancerLong-Term Association Between GLP-1 Receptor Agonist Use and Incident Pancreatic Cancer: A Propensity Score-Matched Retrospective Cohort Study Using the TriNetX Network.

📖 Top 50% JournalArticle

4 days ago • Medicinal chemistry (Shariqah (United Arab Emirates))

Using Computer Design to Create New Oral Drugs for DiabetesComputer-Aided Design of Novel Acrylamido Derivatives as Potential Oral Antidiabetic Agents.

📖 Top 50% JournalArticle

1 week ago • Clinical and experimental hepatology

New treatments for long-term liver diseases focusing on fat-related liver scarringRecent advances in the treatment of chronic liver diseases: focus on MASLD/MASH-related fibrosis.

📖 Top 50% JournalArticle

1 week ago • Canadian journal of physiology and pharmacology

Heart and blood vessel effects of incretin receptor drugs beyond blood sugar controlCARDIOVASCULAR EFFECTS OF INCRETIN RECEPTOR AGONISTS: BEYOND GLYCEMIC CONTROL.

📖 Top 50% JournalArticle

← prevpage 10 of 14next →

GLP-1 Therapies Research Papers